Therapeutic apheresis application using membrane plasma fractionation technology: Present scope and limitations

Therapeutic Apheresis

Volumn 4, Issue 3, 2000, Pages 211-212

  Sueoka, Akinori ^a  

^a Kawasumi Laboratories Inc   (Japan)

Author keywords

Evaflux; Membrane plasma fractionation; Membrane technologies

Indexed keywords

APHERESIS; CONFERENCE PAPER; FRACTIONATION; HEMODIALYSIS; HEMOFILTRATION; PLASMAPHERESIS; PRIORITY JOURNAL;

CHEMICAL FRACTIONATION; EQUIPMENT DESIGN; HUMANS; MEMBRANES, ARTIFICIAL; MOLECULAR WEIGHT; NEEDS ASSESSMENT; PATIENT SELECTION; PLASMAPHERESIS; RESEARCH;

EID: 0033923040     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2000.00218.x     Document Type: Conference Paper

References (4)

1. Sueoka A. Applications of membrane technologies for therapeutic apheresis. Ther Apheresis, 1998;2(4):252-6.
2. Sueoka A. Present status of apheresis technologies: Part 2. Membrane plasma fractionator. Ther Apheresis, 1997;1(2): 135-46.
3. Suehiro T, Sueoka A, Horiuchi J, Takakura K, Tsuda. Y. Clinical evaluation of newly improved EVAL second filters. Ther Plasmapheresis, 1993;12:771-4.
4. Suehiro T, Sueoka A, Horiuchi J, Kojima S, Shiba M, Yamamoto A. Clinical evaluation of plasmapheresis using a newly developed high performance EVAL second filter (Evaflux-5A) for hypercholesterolemia. Jpn J Artif Organs, 1993;22: 243-7.